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H E A L T H  A N D  M E D I C I N E
Osteogenic preconditioning in perfusion bioreactors 
improves vascularization and bone formation by 
human bone marrow aspirates
J. N. Harvestine1, T. Gonzalez-Fernandez1, A. Sebastian2, N. R. Hum2, D. C. Genetos3,  
G. G. Loots2, J. K. Leach1,4*
Cell-derived extracellular matrix (ECM) provides a niche to promote osteogenic differentiation, cell adhesion, survival, 
and trophic factor secretion. To determine whether osteogenic preconditioning would improve the bone-forming 
potential of unfractionated bone marrow aspirate (BMA), we perfused cells on ECM-coated scaffolds to generate 
naïve and preconditioned constructs, respectively. The composition of cells selected from BMA was distinct on 
each scaffold. Naïve constructs exhibited robust proangiogenic potential in vitro, while preconditioned scaffolds 
contained more mesenchymal stem/stromal cells (MSCs) and endothelial cells (ECs) and exhibited an osteogenic 
phenotype. Upon implantation into an orthotopic calvarial defect, BMA-derived ECs were present in vessels in 
preconditioned implants, resulting in robust perfusion and greater vessel density over the first 14 days compared 
to naïve implants. After 10 weeks, human ECs and differentiated MSCs were detected in de novo tissues derived 
from naïve and preconditioned scaffolds. These results demonstrate that bioreactor-based preconditioning aug-
ments the bone-forming potential of BMA.
INTRODUCTION
With nearly 400 currently active and/or recruiting clinical trials in 
the United States (www.clinicaltrials.gov, accessed 16 May 2019), 
bone marrow–derived mesenchymal stem/stromal cells (MSCs) are 
under widespread clinical investigation for their regenerative capacity. 
Bone marrow aspirate (BMA) is a readily available source of hema-
topoietic and mesenchymal progenitor cells for autologous cell 
therapy. Current point-of-care devices concentrate bone marrow 
for direct injection, yet MSCs only comprise 0.01% of nucleated 
cells from the bone marrow (1). Therefore, extended ex vivo culture 
is necessary to produce a sufficient number of MSCs for clinical use. 
However, the high costs associated with Good Manufacturing Practices 
and increased regulatory burden introduced by in vitro culture 
motivate the development of alternative strategies to use BMA.
Preconditioning of cells before transplantation provides critical 
stimuli to guide cell function, and several groups report that pre-
conditioning MSCs in vitro improves their survival and potential 
for tissue formation (2). For example, preconditioning MSCs with 
tetrandrine-activated secretion of prostaglandin E2, an immuno-
suppressive molecule, resulted in decreased inflammation when 
cells were implanted in a mouse model (3). Hypoxic precondition-
ing of MSCs improved cell survival in a subcutaneous site (4), 
angiogenesis in hindlimb ischemia (5), and bone formation in 
critical-sized femoral defects (6). The bone-forming potential of cells 
from lipoaspirates and BMA is increased when cells are expanded in 
perfusion bioreactors compared to traditional monolayer culture 
(7, 8). Additional studies demonstrate that tissue aspirates have 
osteogenic potential when implanted immediately after isolation with 
minimal in vitro manipulation (9). An intraoperative procedure to 
apply autologous cells for tissue regeneration is the preferred strategy 
for clinical translation. However, there are limited studies to deter-
mine whether osteogenic preconditioning of BMAs before implanta-
tion will improve bone formation. Furthermore, the interplay of soluble 
(e.g., inductive factors) and substrate-mediated cues (e.g., extracellular 
matrices) on BMA for bone formation in three-dimensional (3D) 
perfusion culture is unknown.
Extracellular matrix (ECM) provides soluble and insoluble cues 
to direct cell adhesion, migration, differentiation, and tissue-specific 
functions (10). Bottom-up biomaterial design efforts aim to recapit-
ulate cellular responses to key ECM components (11, 12). However, 
these approaches fail to mimic the diverse and complex composition 
of cell-derived ECM, thereby restricting the advantageous contribu-
tion of diverse ligands to direct cell fate. Cell-secreted ECM generated 
in vitro maintains the complex nature of ECM and has been used as 
a surface coating of 3D materials to direct osteogenic differentiation 
for bone tissue engineering (13, 14). In combination with perfusion 
bioreactors, ECM on ceramic scaffolds successfully sequestered cells 
from BMA and recapitulated a bone marrow niche capable of sup-
porting both differentiated and hematopoietic progenitor cells after 
isolation (15). We recently demonstrated that ECM-coated scaffolds 
enrich endothelial and MSC subpopulations from BMA, but we did 
not observe differences in bone formation when scaffolds were 
implanted into an ectopic site (16). Whether preconditioning BMA 
in the presence of ECM affects the osteogenic potential of the 
construct is unknown.
We hypothesized that osteogenic preconditioning of cells from 
BMA on an ECM-coated scaffold would improve bone formation 
upon implantation (Fig. 1). To investigate this hypothesis, we assessed 
the ability of ECM-coated scaffolds to sequester cells from un-
processed BMA. We then examined the effect of in vitro precondition-
ing in a perfusion bioreactor to prompt neovascularization and bone 
regeneration versus nonconditioned BMA in an orthotopic bone 
defect model.
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RESULTS
Preconditioning promotes the expansion of MSCs 
and endothelial cells from BMA
Scaffolds maintained structural integrity and overall morphology 
after both culture durations (20 hours and 14 days) (Fig. 2A). We 
used flow cytometry to determine the immunophenotype of cells 
before and after culture (Fig. 2, B to D). Myeloid cells (CD45+ CD31−) 
constituted approximately 80% of cells from fresh BMA, and this 
proportion was maintained over the 20-hour perfusion (P = 0.9175) 
to produce naïve constructs (Fig. 2B). However, this proportion was 
reduced over 14 days of osteogenic preconditioning to approximately 
6% of cells (P < 0.0001). The fraction of MSCs (CD73+CD90+ CD45−) 
in the fresh BMA (0.2%) was increased to 0.8 and 6.5% in naïve 
(P = 0.8659) and preconditioned (P = 0.001) constructs, respectively 
(Fig. 2C). We also observed a 17-fold increase in the percentage of 
endothelial cells (ECs; CD31+CD45−) during in vitro precondition-
ing (P = 0.003) (Fig. 2D). Scanning electron microscopy (SEM) 
revealed that cells on naïve constructs were often rounded and 
located along the periphery of pores, while cells in preconditioned 
grafts exhibited pore-spanning, stretched morphologies (Fig. 2E).
Duration of bioreactor preconditioning influences  
construct phenotype
We performed RNA sequencing (RNA-seq) on cells retrieved from 
BMA, naïve, and preconditioned constructs to determine how bio-
reactor seeding and preconditioning affected cell phenotype. We 
also performed quantitative polymerase chain reaction (qPCR) to 
validate the expression of key osteogenic and angiogenic genes. In 
agreement with the flow cytometry data, preconditioning significantly 
reduced the expression of genes associated with immune and inflam-
matory events expressed by myeloid-derived cells (fig. S1 and table S1). 
Critical genes associated with osteogenic differentiation—COL1A1, 
COL1A2, MGP, SPP1, PHEX, and BMP-2—were significantly up- 
regulated in preconditioned constructs (Fig. 3A, osteogenesis heat-
map, and table S2) compared to naïve scaffolds. RUNX2, the master 
transcription factor for osteogenesis, was also up-regulated in pre-
conditioned constructs compared to naïve constructs, yet it had the 
highest expression in BMA (table S2). Expression of BGLAP, the gene 
encoding for osteocalcin (OCN), was extremely low in both naïve 
and preconditioned constructs, suggesting that the preconditioned 
cells are more likely immature osteoblasts at day 14. Expression of 
several genes associated with vasculature development, including VEGFC, 
PDGFA, PGF, PDPN, and EFNB2, was significantly up-regulated in 
preconditioned scaffolds compared to naïve constructs (Fig. 3A, 
vasculature development heatmap, and table S3). However, expres-
sion of VEGFA, encoding for the potent angiogenic protein vascular 
endothelial growth factor (VEGF), was greatest in naïve constructs 
(table S3).
qPCR confirmed RNA-seq expression of RUNX2, SP7, and BGLAP 
(Fig. 3, C to E). In contrast, genes associated with later stages of 
osteogenic differentiation, IBSP, COL1A1, and BMP-2, were up- 
regulated in preconditioned constructs (Fig. 3, F to H) compared to 
naïve scaffolds. In agreement with both RNA-seq and qPCR results 
(Fig. 3B), VEGF secretion was greater in naïve constructs (Fig. 3I), 
while bone morphogenetic protein-2 (BMP-2) secretion was greater 
in preconditioned constructs (Fig. 3K). Despite low BGLAP expression 
Fig. 1. Schematic of experimental design. (A) Medium containing cell-secreted ECM was mixed with (B) mononucleated cells from BMA and seeded onto (C) HA–
poly(lactide- co-glycolide) (PLG) scaffolds using a perfusion bioreactor. After 20 hours of perfusion, (D) naïve scaffolds were retrieved, and (E) preconditioned scaffolds 
were perfused with culture medium containing osteogenic supplements for 13 additional days. (F) Scaffolds were implanted into 3.5-mm bilateral calvarial defects.
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in both naïve and preconditioned constructs, we observed greater 
OCN secretion by cells on preconditioned constructs (Fig. 3J). 
Immunohistochemistry revealed greater OCN presence in the ECM 
of preconditioned grafts (Fig. 3M). All constructs were coated with 
cell-secreted ECM during cell seeding, evidenced by positive stain-
ing with picrosirius red in naïve grafts (Fig. 3L, left). Entrapped cells 
continued to deposit a collagenous ECM during preconditioning 
evidenced by greater collagen content in preconditioned grafts 
(Fig. 3L, right). We analyzed the mineral content of the naïve and 
preconditioned groups at day 14 of in vitro culture through micro-
computed tomography (micro-CT) and Alizarin Red staining of 
mineral deposition. Mineral content established by bone volume 
(BV) and calcium staining was visibly greater in the naïve group 
than in the preconditioned scaffolds, likely due to hydroxyapatite 
(HA) degradation during preconditioning (fig. S2).
Preconditioned grafts improve neovascularization 
of implants
Both naïve and preconditioned constructs exhibited increasing levels 
of vascularization during the first 2 weeks after implantation when fol-
lowed with laser Doppler perfusion imaging (LDPI; Fig. 4, A and C). 
At day 14, defects treated with preconditioned grafts exhibited sig-
nificantly increased perfusion compared to defects filled with naïve 
constructs (P = 0.042). The greatest level of perfusion across the 
whole study was observed at this time point. Perfusion in defects 
treated with naïve grafts peaked at day 28 and was significantly 
higher than those treated with preconditioned scaffolds at day 35. 
At the conclusion of the study (day 70), perfusion was similar in 
both groups. In agreement with LDPI, we observed increased vessel 
density in preconditioned grafts (P = 0.0017) when evaluating 
histology of explants at 2 weeks (Fig. 4B). Staining against human- 
specific CD31 revealed the presence of human ECs in both naïve 
and preconditioned implants, yet blood vessels of human origin were 
only observed in preconditioned grafts (Fig. 4D).
Hematoxylin and eosin (H&E)–stained sections revealed cellu-
lar infiltration into both naïve and preconditioned constructs after 
2 weeks (Fig. 4E). Patches of early woven bone and osteoid were 
observed in sections stained with Masson’s trichrome (Fig. 4F). Im-
munostaining for OCN revealed more prominent staining in naïve 
constructs compared to preconditioned constructs, which more closely 
Fig. 2. Preconditioning increases MSC and EC content in osteogenic grafts. (A) Gross morphology images of (left) naïve and (right) preconditioned grafts after culture. 
Scale bar, 4 mm. (B to D) Percentage of cells that are (B) hematopoietic (CD45+CD31−), (C) endothelial (CD31+CD45−), and (D) mesenchymal (CD73+CD90+CD45−) in origin 
(n = 4 to 5). (E) Representative SEM images of (left) naïve and (right) preconditioned grafts false-colored to show cells in purple, ECM in orange, and scaffold in blue. Scale 
bar, 500 m.
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Fig. 3. In vitro culture duration modulates phenotype of entrapped cells. (A) Heatmaps representing RNA-seq data of 20 key regulators of osteogenesis and vascular 
development up-regulated in preconditioned compared to naïve constructs (n = 3 to 4). (B to H) Relative expression of genes involved in proangiogenic potential and 
osteogenic differentiation as a function of duration in perfusion culture (n = 5). (I) Proangiogenic and (J and K) osteogenic protein secretion (n = 5 to 6). Histological 
sections stained with (L) picrosirius red (scale bar, 500 m) and (M) anti-OCN (scale bar, 100 m). Red arrows denote positive staining, and black arrows denote scaffold. 
*P < 0.05, ***P < 0.001, ****P < 0.001.
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resembled the staining present in the native bone present on the 
defect margins (Fig. 4G).
Preconditioning improves bone formation
Bioreactor culture duration did not alter the resultant BV or average 
mineral density in acellular constructs, and the addition of cells 
in naïve constructs did not enhance bone formation over acellular 
controls. Significant increases in BV (P = 0.019) (Fig. 5A) and cor-
responding values for average mineral density throughout the 
defects (P = 0.041) were observed in preconditioned constructs com-
pared to all other groups. However, the newly formed bone mineral 
density was similar across all groups (P > 0.478) (Fig. 5B). Repre-
sentative micro-CT images demonstrate uniform bone formation 
throughout the surface and volume of preconditioned implants com-
pared to naïve implants that exhibit islands of mineralized tissue (Fig. 
5C). We observed a moderate correlation between the day 14 perfu-
sion values versus BV (P = 0.01, r2 = 0.48) and average mineral density 
(P = 0.01, r2 = 0.49) (Fig. 5D, left). When the implant with the greatest 
perfusion is compared to the implant with the least perfusion, we ob-
served an appreciable increase in bone formation (Fig. 5D, right).
Histological staining confirmed new bone formation in sections 
stained with H&E and Masson’s trichrome (Fig. 6, A and B). Pre-
conditioned scaffolds resulted in better integration with host bone 
compared to naïve scaffolds (fig. S3). Staining with human-specific 
anti-CD31 revealed the presence of human ECs and human-derived 
vasculature in both naïve and preconditioned implants after 10 weeks 
(Fig. 6C), unlike 2-week explants that did not include human CD31+ 
cells within the vasculature of naïve constructs. Similarly, staining 
with human-specific anti–distal-less homeobox 5 (DLX5), a marker 
of MSC osteogenesis (17), revealed the presence of human- derived 
MSCs undergoing osteogenic differentiation in both the naïve and 
preconditioned implants after 10 weeks of in vivo implantation 
Fig. 4. Preconditioned grafts enhance early vascularization. (A) Raw perfusion values from LDPI (n = 6). (B) Quantification of vessel density (n = 3). (C) Representative 
LDPI images color mapped to reveal the magnitude of perfusion quantified from the defect area denoted by a red circle. Scale bar, 3.5 mm. (D) Immunostaining for human 
CD31. Black arrows denote vessel structures, and red arrows denote positive staining for non–vessel-forming cells. Scale bar, 100 m. (E) Hematoxylin and eosin (H&E), 
(F) Masson’s trichrome, and (G) anti-OCN staining. Scale bar, 1 mm. New woven bone is denoted B. *P < 0.05, **P < 0.01.
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(Fig. 6, D to G). These results confirm the presence of the trans-
planted human cells and their essential role in the development of 
new vasculature and bone tissue at the site of implantation.
DISCUSSION
The delivery of bone marrow–derived MSCs to augment tissue 
repair is at the forefront of regenerative medicine for orthopedic 
indications, including avascular necrosis of the femoral head (18) and 
cartilage lesions (19). Current technologies concentrate nucleated cells 
from BMA but are unable to select for MSCs that have osteogenic 
potential and a complex secretome that recruits endogenous cells 
for tissue regeneration. Clinical outcomes demonstrate a positive 
correlation between the number of colony forming units and bone 
formation by autologous BMA injection (20), yet MSCs represent 
0.01% of nucleated cells from BMA (1) and require culture expansion 
to generate clinically relevant cell numbers. Bone formation has been 
reported when implanting tissue aspirates after minimal ex vivo 
culture and cell expansion using perfusion bioreactors (7, 8, 21). 
However, a direct comparison of uncultured and preconditioned 
BMA has not been reported. Here, we describe the effect of osteogenic 
preconditioning via perfusion bioreactor culture on the bone- forming 
capacity of BMA.
Bioreactors are an effective and scalable strategy for MSC expan-
sion compared to traditional monolayer culture (7, 22, 23). Beyond 
expansion, perfusion flow-induced shear stress promotes an osteogenic 
phenotype (24) and deposition of a mineralized ECM by MSCs 
(25, 26). Thibault et al. (14) reported that murine bone marrow–derived 
MSCs cultured in short-term perfusion culture deposited an ECM rich 
in collagen I, HA, and matrix-remodeling proteins. Perfusion culture 
can be used to populate implantable biomaterials with cells from tissue 
aspirates to locally concentrate and activate cells in the defect site. In 
this study, naïve constructs maintained similar cell composition to 
freshly isolated BMA and expressed high levels of transcripts associated 
with myeloid cell fate. In contrast, preconditioned constructs contained 
fewer hematopoietic cells and increased proportions of both MSCs 
and ECs. Consistent with cells undergoing osteogenic differentiation, 
preconditioning resulted in high expression of several markers of 
Fig. 5. Early vascularization correlates with bone formation by preconditioned grafts. (A) BV. (B) Bone mineral density. For (A) and (B), n = 5 for controls and n = 7 for 
experimental groups (*P < 0.05). (C) Representative micro-CT images of defects at 10 weeks after implantation. (D) Correlations between perfusion at 14 days and 10-week 
BV (P = 0.01, r2 = 0.48) and bone mineral density (P = 0.01, r2 = 0.49). Lowest and highest perfusion values are denoted with blue and red points, respectively, and connected 
via arrows to corresponding LDPI and micro-CT images.
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osteogenesis, yet the molecular profiling suggested that osteoblasts 
within these constructs were immature. Immunohistochemistry, how-
ever, showed increased secretion of OCN that could be indicative of 
either a slower protein turnover or a slightly more mature stage of 
osteoblasts in these constructs. Preconditioned constructs had reduced 
expression and secretion of VEGF-A yet expressed several other pro-
angiogenic genes at a higher level. It is unclear which differentiation 
stage the MSCs within the BMA have achieved after 14 days, but this 
is further complicated by the heterogeneity of the aspirate, donor 
variability, and the inability to specifically analyze changes in differ-
entiation stage of subpopulations within the graft with the studies as 
designed. RNA-seq data demonstrate the increasing expression of 
multiple osteogenic genes in the preconditioned scaffolds compared 
to naïve scaffolds, providing further evidence that cells within the graft 
are undergoing osteogenic differentiation. We also demonstrate by 
RNA-seq that many genes associated with vascular development are 
up-regulated in preconditioned scaffolds, which is in contrast to 
data establishing the inverse relationship between osteogenesis and 
angiogenic potential in human MSCs (27, 28). These results indicate 
that 14 days of osteogenic preconditioning in perfusion bioreactors 
is sufficient to shift cellular differentiation toward bone-forming cells, 
yet the osteoblasts are still immature. A longer preconditioning span 
may further enhance osteogenesis of these constructs.
HA provides an osteoconductive surface and is widely used in 
bone regeneration (7, 29, 30). Moreover, HA scaffolds coated with 
cell-derived ECM were recently used to recapitulate the bone marrow 
Fig. 6. Human ECs and MSCs engraft into new bone tissue. (A to C) Histological sections stained with (A) H&E, (B) Masson’s trichrome, and (C) anti-human CD31. B and 
O denote new bone and osteoid, respectively, and black arrows denote vasculature of human origin. Scale bars, 100 m. (D to G) Immunofluorescence staining of histo-
logical sections for anti-human DLX5 (magenta) and cell nucleus (blue). (D and E) (Top) Naïve and (bottom) preconditioned (D) acellular and (E) BMA-loaded scaffolds 
compared to (F) uncoated acellular and (G) sham controls. Scale bars, 100 m.
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niche and support hematopoiesis by fresh BMAs in vitro using per-
fusion bioreactors (15). For clinical application, it is important that 
materials are easily handled and amenable to modifications using 
tools readily available in the operating theater. On its own, HA is brittle 
and difficult to cut to the shapes and sizes needed for irregular defects. 
In this study, we fabricated a composite scaffold with a 2.5:1 weight 
ratio of HA to poly(lactide-co-glycolide) (PLG) microspheres, a Food 
and Drug Administration (FDA)–approved biodegradable polymer. 
In previous studies, this formulation promoted osteogenic differentia-
tion concomitant with sustained VEGF secretion by MSCs in vitro and 
robust bone formation in vivo (31). The formation of scaffolds from 
PLG microspheres provides additional opportunities to incorporate 
biomacromolecules with controlled release kinetics to instruct cell 
function (32). Mineral content was reduced in preconditioned scaf-
folds compared to naïve constructs, likely due to HA degradation 
during the culture period. Despite the lack of mineralization at the 
time of implantation, preconditioned constructs induced superior 
healing in the calvarial defect model.
The necessity of revascularization during bone regeneration is well 
characterized, further motivating treatments that promote efficient 
vessel infiltration. VEGF-releasing PLG scaffolds successfully increased 
vessel density and resulted in bone regeneration of irradiated calvarial 
defects (32). Delivery of culture-expanded MSCs with various EC 
populations also improved vascularization and subsequent bone for-
mation (33, 34). This successful approach requires isolation of ECs 
from a secondary compartment, and it would be advantageous to 
deliver MSCs and ECs derived from the same tissue aspirate. How-
ever, MSCs and ECs represent a very small fraction of cells from 
BMA, and strategies to simultaneously expand both populations are 
lacking, motivating the need for strategies to sequester and promote 
expansion of these cells from BMA.
Cell-derived ECM is a biomimetic platform that increases MSC 
adhesion, survival, proliferation, trophic factor secretion, and osteo-
genic differentiation of associated MSCs (13, 25, 35). Cell-derived 
ECM was an effective material to retain endothelial and accessory 
cells from lipoaspirates and promote osteogenic differentiation with-
in the resultant heterogenous cell population (36). In this study, we 
sought to determine whether preconditioning BMA before implan-
tation was sufficient to increase bone formation. Datta et al. (37) 
reported the benefit of in vitro–generated ECM when perfusing and 
decellularizing scaffolds as a platform for MSC osteogenic differentia-
tion. ECM produced in monolayer culture should be more consistent 
in composition than ECM deposited on constructs under perfusion 
that experience variation in shear stress and nutrient availability. 
The ECM used herein has been well characterized and is consistent 
across several donors. We and others have evaluated the impact 
of in situ ECM-coated scaffolds, demonstrating that more mature 
osteogenic grafts generated in vitro translate to improved bone for-
mation in vivo. By coating scaffolds with ECM before preconditioning, 
we sought to accelerate this process. In agreement with our previous 
study (36), preconditioning of BMA via perfusion culture in the 
presence of ECM successfully retained and expanded the endothelial 
population concomitant to osteogenic differentiation by MSCs. 
Preconditioned constructs exhibited increased secretion of BMP-2, 
a potent osteoinductive molecule produced by ECs in coculture 
(29, 38). The established synergy between MSC and EC populations 
in coculture improved EC vasculogenic capacity upon implantation 
(39) and improved MSC engraftment and regenerative capacity (40). 
In agreement, we observed persistence and engraftment of implanted 
ECs and MSCs throughout the 10-week study. ECs were observed 
within the lumen of vessel structures, and MSCs were positive for 
osteogenic differentiation marker, DLX5, demonstrating respective 
functional roles during new tissue formation. These data demonstrate 
that MSCs can directly participate in bone formation when provided 
appropriate cues and are not limited only to trophic factor secretion.
The pivotal role of angiogenesis during endochondral ossification 
(41) and intramembranous ossification (32) is well established. Despite 
limited VEGF expression and secretion, preconditioned implants 
resulted in robust vascular infiltration within 2 weeks in vivo. More-
over, we observed human-derived vasculature after 2 weeks in vivo, 
indicating that implanted ECs participated in neovascularization to 
quickly perfuse preconditioned constructs. Despite greater pro-
angiogenic potential in vitro, naïve grafts exhibited maximum per-
fusion 2 weeks later at 28 days after implantation. Upon explantation 
at the conclusion of the study, we observed human cells within the 
vasculature of both naïve and preconditioned implants, indicating 
that ECs implanted in naïve constructs also participated in vessel 
formation. Even in preconditioned constructs, ECs represented a 
relatively small fraction of implanted cells, and the presence of human 
ECs after 10 weeks in vivo demonstrates prolonged cell survival and 
engraftment into newly formed tissue. Furthermore, early vascular-
ization correlated to increased bone formation, suggesting that invad-
ing vasculature played a key role in bone formation. Preconditioned 
scaffolds were better integrated with host bone compared to naïve 
constructs. These data indicate that preconditioning increased the 
rate of vascular infiltration into implanted scaffolds. However, without 
more frequent sample collections, these data are insufficient to fully 
describe the contribution of vascular pruning and remodeling after 
initial vascular infiltration on resultant bone regeneration. Future studies 
evaluating these interactions are merited to better understand the 
interplay between vascular maturation and bone formation.
Healing within these subcritical-sized defects was expected over 
the course of the study, and the observed differences may reflect 
changes to the rate of healing as a result of preconditioning. For 
example, samples were stained for the presence of OCN both before 
and after implantation to assess the progression of osteogenic matrix 
deposition during healing. We observed strong staining for OCN in 
the ECM of preconditioned constructs before implantation and naïve 
implants after 14 days in vivo. In contrast, OCN staining decreased 
in preconditioned implants in vivo, which appeared more similar to 
the native bone at the defect margins. However, BGLAP expression, the 
gene encoding for OCN, was low in both naïve and preconditioned 
scaffolds in vitro. The discrepancy in BGLAP transcript expression, 
identified by RNA-seq data and confirmed by qPCR, versus protein 
levels identified by enzyme-linked immunosorbent assay (ELISA) 
and immunohistochemistry was initially puzzling. Reduced BGLAP 
expression could result from the heterogeneous population of cells 
within the construct, although that may not explain the reductions 
that were also observed by RNA-seq. RNA-seq demonstrates the 
overwhelming evidence that osteogenic genes are more highly up- 
regulated with increasing culture time in perfusion. Transcriptional 
regulation of BGLAP is complex, revealing a species-specific response 
to vitamin D3 (42) and differential transcriptional versus post- 
transcriptional regulation depending on cell phenotype, with tran-
scription outpacing protein product in immature osteoblasts, whereas 
protein synthesis is greater than transcription in mature osteoblasts 
(43). As scaffolds undergo continued remodeling in vivo, OCN 
incorporated within the scaffold during preconditioning was likely 
Harvestine et al., Sci. Adv. 2020; 6 : eaay2387     12 February 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 12
liberated from the scaffold. The occurrence of remodeling in vivo is 
evident by the reduction in BV in naïve scaffolds at the conclusion 
of the study compared to preimplantation, wherein BV decreased 
from ~9 mm3 (fig. S2A) to ~0.6 mm3 (Fig. 5A). Conversely, there 
was little mineral content in preconditioned scaffolds upon implan-
tation (fig. S2A), whereas robust BV (~1.5 mm3) was evident at the 
conclusion. We also observed earlier neovascularization and implant 
perfusion in preconditioned implants, suggesting that preconditioning 
accelerated the rate of healing in vivo. While we observed angiogenic 
and osteogenic advantages due to preconditioning over the course of 
this study, it is difficult to predict whether these advantages would 
improve overall quality of bone formation after complete healing.
To our knowledge, this is the first report that directly compares 
the bone-forming potential of freshly isolated versus preconditioned 
human BMA in an orthotopic bone defect. From a translational 
perspective, it is advantageous to collect and deliver autologous cells 
during a single procedure without the need for ex vivo culture. 
However, the emergence of FDA-approved tissue engineering products 
such as MACI (Vericel Corporation, Cambridge, MA)—in which 
autologous chondrocytes are collected, shipped off-site, cryopreserved, 
expanded, and then reimplanted into the patient—demonstrates 
that these strategies are clinically and commercially feasible if they 
add therapeutic value. In this study, a relatively short in vitro culture 
duration significantly improved vascularized bone formation by BMA. 
Preconditioned grafts contained increased numbers of MSCs, and 
cells on these constructs expressed genes and deposited ECM consistent 
with osteogenic differentiation before implantation. Therefore, it is 
difficult to decouple the effects of delivering osteogenically primed 
MSCs versus simply delivering a larger number of MSCs to the defect 
site. However, transplantation of larger numbers of cells can yield 
diminishing returns due to massive cell death and insufficient nutrient 
availability. Furthermore, craniofacial bones heal via intramembranous 
ossification that relies on differentiating osteoprogenitor cells such 
as those present in preconditioned implants to mineralize the tissue. 
Long bones in the skeleton are formed and undergo repair via endo-
chondral ossification, which requires the formation of a cartilaginous 
template before vascular infiltration and mineralization. The implanta-
tion of hypertrophic cartilaginous constructs, achieved over 3 to 6 weeks 
in culture, has successfully achieved vascularized bone regeneration 
in long bones (30, 44). In contrast to the preconditioning performed 
here, which delivered ECs and MSCs to the defect site for rapid vascular-
ization, preconditioning strategies that instruct the formation of a 
hypertrophic cartilage phenotype may prove more successful in long 
bone regeneration. Therefore, an optimal preconditioning regimen 
for concomitant chondrogenic and osteogenic preconditioning of 
MSCs and ECs before implantation into long bone defects merits 
further study. While these comparative studies are beyond the scope 
of this work, our results herein demonstrate that preconditioning of 
BMA on ECM-coated scaffolds generates a robust osteogenic graft 
containing a heterogeneous population of human cells that enhances 
bone healing.
MATERIALS AND METHODS
ECM production
Human bone marrow–derived MSCs (Lonza, Walkersville, MD) were 
used without further characterization. MSCs were expanded until 
use at passages 5 and 6 in minimum essential medium– [-MEM; 
with l-glutamine and without ribo/deoxyribonucleosides (Invitrogen, 
Carlsbad, CA)] supplemented with 10% fetal bovine serum (FBS; 
Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin (10,000 
U ml−1) and streptomycin (10 mg ml−1; Mediatech, Manassas, VA) (P/S). 
Cell-secreted ECMs were prepared as we described (28, 35, 45, 46). 
Briefly, MSCs were seeded at 50,000 cells cm−2 and cultured in medium 
supplemented with ascorbate 2-phosphate (50 g ml−1) for 10 days 
with medium changes every 2 to 3 days. After culture, monolayers 
were washed with phosphate-buffered saline (PBS), and cells were 
removed using a detergent-based solution, followed by deoxyribo-
nuclease (Sigma-Aldrich, St. Louis, MO) treatment (37°C for 1 hour) 
to remove 99.9% of DNA content from culture after decellularization 
(45). Decellularized ECM was washed three times with PBS and 
mechanically dislodged from culture flasks using a cell scraper. Total 
protein within the collected ECM was quantified using a bicinchoninic 
acid protein assay (Thermo Fisher Scientific, Rockford, IL). ECM 
solutions were frozen in 0.02 N acetic acid at −20°C until use.
Composite scaffold fabrication
Scaffolds were fabricated using a gas foaming/particulate leaching 
method as previously described (16, 31, 47). Microspheres composed 
of PLG (85:15; DLG 7E; Lakeshore Biomaterials, Birmingham, AL) 
were prepared using a double-emulsion process and lyophilized to 
form a free-flowing powder. Lyophilized microspheres (9.2 mg) 
were combined with 23.1 mg of HA crystals (particle size, 100 nm; 
Berkeley Advanced Biomaterials, Berkeley, CA) and 175.6 mg of 
NaCl (300 to 500 m in diameter) to yield a 2.5:1:19 mass ratio 
of ceramic:polymer:salt. The powdered mixture was compressed 
under 2 metric tons for 1 min to form solid disks (final dimensions, 
8 mm in diameter and 2 mm in height) using a Carver Press (Carver 
Inc., Wabash, IN). Compressed disks were exposed to high-pressure 
CO2 gas (5.5 MPa) for at least 16 hours, followed by rapid pressure 
release to prompt polymer fusion. Salt particles were leached from 
scaffolds in distilled H2O for 24 hours to generate HA-PLG composite 
scaffolds. Scaffolds were sterilized by 70% ethanol under gentle vacuum, 
followed by two rinses in sterile PBS.
Seeding BMA in perfusion bioreactors
Unprocessed human BMA was from Lonza [10 ml of aspirate from 
n = 3 donors (two males and one female; 21 to 26 years old; mean 
age, 23 ± 2.5 years)]. BMA was diluted 1:5 in PBS and pelleted by 
centrifugation at 1000g. Cells were incubated in a red blood cell lysis 
buffer (154.4 mM ammonium chloride, 10 mM potassium bicarbonate, 
and 97.3 mM EDTA tetrasodium salt) for 5 min at 37°C and washed 
with PBS, and viable cells were quantified using a Countess II Auto-
mated Cell Counter (Thermo Fisher Scientific). Culture medium was 
prepared with equal parts of -MEM supplemented with 10% FBS and 
1% P/S, Microvascular Endothelial Growth Medium-2 (EGM-2MV), 
and RPMI 1640 supplemented with 10% FBS and 1% P/S. Bioreactor 
seeding was performed as previously described (16, 47, 48). Briefly, 
scaffolds were installed into U-CUP flow perfusion bioreactors (CEL-
LEC BIOTEK, Basel, Switzerland), and 10 ml of medium was injected 
into the bottom port. Medium was further supplemented with ECM 
(100 g ml−1) to produce ECM-coated scaffolds (Fig. 1A). Cells were 
resuspended in medium with ECM, and 2 ml of solution was injected 
as described (Fig. 1B). Bioreactors were perfused at a superficial veloc-
ity of 3 ml min−1 for 20 hours to seed the constructs (Fig. 1C). Scaf-
folds collected or implanted after the 20-hour seeding duration were 
referred to as naïve scaffolds (Fig. 1D). To generate preconditioned 
scaffolds, medium was refreshed after 20 hours and then every 2 to 
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3 days with osteogenic medium [culture medium supplemented with 
ascorbate 2-phosphate (50 g ml−1), 10 mM -glycerophosphate, 
and 10 nM dexamethasone (all from Sigma-Aldrich)] for a total of 
14 days (Fig. 1E).
Immunophenotype of entrapped cells
Entrapped cells were liberated from scaffolds through enzymatic and 
mechanical digestion. Scaffolds were washed with PBS, followed by 
perfusion of 12 ml of trypsin for 5 min at 37°C. Trypsin was retrieved 
from the bioreactors and added to an equal volume of medium. 
Scaffolds were removed from bioreactors, minced, and immersed in 
trypsin for an additional 5 min at 37°C in a tube rotator (Thermo 
Fisher Scientific, Santa Clara, CA) at 15 rpm. The immunophenotype 
of retrieved cells was determined using flow cytometry. Briefly, non-
specific binding was blocked by incubation in Protein Block (AB156024, 
Abcam, Cambridge, MA) for 20 min and then incubated with anti-
bodies against CD31 (303110), CD45 (368518), CD34 (343623), CD90 
(328112), and CD73 (344008) (all from BioLegend, San Diego, CA) 
per the manufacturer’s instructions.
Gene expression and protein secretion
To interrogate osteogenic and proangiogenic gene expression, 
samples were collected in TRIzol Reagent (Invitrogen) for PCR 
analysis following the manufacturer’s instructions. After RNA 
isolation, 600 ng of RNA was reverse-transcribed with the QuantiTect 
Reverse Transcription Kit (QIAGEN, Valencia, CA), and qPCR was 
performed using the QuantiFast Probe PCR Kit (QIAGEN) on a 
QuantStudio 5 system (Applied Biosystems). Primers and probes 
for housekeeping genes RPL13 (Hs00744303_s1), RUNX2 
(Hs01047973_m1), SP7 (Hs01866874_s1), BGLAP (Hs01587814_g1), 
IBSP (Hs00173720_m1), COL1A1 (Hs00164004_m1), BMP-2 
(Hs00154192_m1), and VEGF-A (Hs00900055_m1) were purchased 
from Thermo Fisher Scientific. Amplification conditions were 95°C 
for 3 min, followed by 45 cycles at 95°C for 3 s and 60°C for 30 s. 
qPCR results were normalized to RPL13 transcript levels to yield 
Ct and cells from fresh BMA to yield Ct. Last, fold change in 
expression relative to the untreated and housekeeping gene was 
calculated using 2−Ct. Osteogenic and proangiogenic protein 
secretions were assessed by quantifying VEGF, OCN, and BMP-2 
secretion with protein-specific ELISA kits per the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN).
RNA-seq library preparation was performed using Illumina 
TruSeq RNA Library Preparation Kit v2 (catalog no. RS-122-2002, 
Illumina), and single-end 75–base pair sequencing was performed 
using an Illumina NextSeq 500. Sequencing data quality was checked 
using FastQC software (www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Reads were mapped to the human genome (hg38) using STAR 
(49), and read counts per gene were determined using “featureCounts” 
from Rsubread package (50). Differentially expressed genes were 
identified using limma after voom normalization (51). A gene was 
considered as significantly differentially expressed when its false 
discovery rate–adjusted P value was <0.05 and fold change was >2. 
Gene ontology enrichment analysis was performed using ToppGene 
(52). Heatmaps were generated using the heatmap.2 function in 
“gplots” R package.
Histological analysis and SEM
Scaffolds were fixed in 10% formalin acetate overnight at 4°C, washed 
two times with water, soaked overnight in optimal cutting temperature 
(OCT) compound, frozen, and sectioned at 5 m. Collagenous ECM 
was visualized with a picrosirius red stain using standard protocols, 
and the presence of OCN, an osteogenic ECM protein, was detected 
using a primary antibody against OCN (1:200; AB13420, Abcam).
Cell morphology was visualized with SEM (35, 47). Scaffolds were 
fixed in freshly prepared Karnovsky’s fixative solution overnight at 
4°C, washed twice with water, bisected, and dehydrated in increasing 
concentrations of ethanol. Following dehydration, samples were critical 
point dried (Supercritical Autosamdri-931, Tousimis Research Corp., 
Rockville, MD), fixed to stubs with silver paste, sputter-coated with 
gold (Pelco SC-7 Auto Sputter Coater), and imaged using a scanning 
electron microscope (Quattro ESEM, Thermo Fisher Scientific, 
Newington, NH).
Evaluation of scaffold in rat orthotopic bone defect
Rats underwent bilateral calvarial osteotomies as previously described 
(53, 54), and treatment of experimental animals was in accordance 
with University of California, Davis animal care guidelines and all Na-
tional Institutes of Health animal handling procedures. Ten-week-old 
male nude rats (Taconic Biosciences, Germantown, NY) were anes-
thetized (3.0%) and maintained (1.5%) under an isoflurane/O2 mix-
ture delivered through a nose cone at 6 liters min−1. A mid-longitudinal 
15-mm skin incision was made on the dorsal surface of the cranium. 
The periosteum was completely cleared from the surface of the cra-
nial bone by scraping. A trephine bur was used to create one circu-
lar 3.5-mm-diameter defect in the rat cranium on each side of the 
sagittal suture, and the full thickness (~1 mm) of the cranial bone 
was removed. Implants were generated with a final diameter of 
3.5 mm using a biopsy punch and immediately placed directly into 
the osteotomy site—randomizing the side that received a cellular 
implant. Each animal received two implants: a naïve or precondi-
tioned construct and an acellular control that had been exposed 
to perfusion culture for the same duration as its cellular counter-
part (Fig. 1F). Animals were euthanized at 2 or 10 weeks after im-
plantation, and calvariae were collected and fixed in 10% buffered 
formalin acetate for 1 day at 4°C. Samples were washed twice in 
deionized water to remove residual formalin acetate and preserved 
in 70% ethanol at 4°C until further processing.
Qualitative and quantitative 3D analyses of explants at 10 weeks 
were conducted using micro-CT (28, 47). Explants were imaged 
(70 kilovolt peak, 114 A, 300-ms integration time, average of three 
images) using a high-resolution micro-CT specimen scanner (mCT 
35, Scanco Medical, Brüttisellen, Switzerland). Contiguous slices of 
2048 pixels by 2048 pixels were imaged with 15-m resolution and 
slice thickness (voxels). Serial tomograms were reconstructed from 
raw data of 1000 projections per 180° using a cone beam filtered 
back projection algorithm (31). The tomograms were calibrated to 
0.0, 99.6, 200.0, 401.0, and 800.3 mg HA cm−3 concentrations of HA 
so that gray values of the images were converted to units of density 
in milligrams of HA per cubic centimeter. The entire defect was 
analyzed by selecting a 3.5-mm-diameter region of interest extend-
ing through the bone thickness. Material in the reconstructed 
images was partitioned by a threshold of 256 to 3000 mg HA cm−3 
to discriminate between mineralized and unmineralized tissue. 
After thresholding, the image noise was reduced using a low-pass 
Gaussian filter (𝜎 = 0.8, support = 1). BV fraction [BV/TV (total 
volume)] was determined by dividing the number of pixels rep-
resenting bone tissue (BV) by the number of pixels in the cylindrical 
segment (TV).
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After micro-CT analysis, explants were demineralized in Calci- 
Clear (National Diagnostics, Atlanta, GA) for 7 days, washed twice 
in water, dehydrated, paraffin-embedded, and sectioned at 5 m 
thickness. To visualize tissue formation and morphology, sections 
were stained with H&E and Masson’s trichrome. Blood vessel 
density at 10 days was quantified using H&E-stained cross sections 
by counting circular structures with well-defined lumens. To detect 
the persistence of human ECs, sections were immunostained with a 
primary antibody against human CD31 (1:50; AB28364, Abcam). 
To detect osteogenic human MSCs, sections were immunostained 
with a primary antibody against human DLX5 (10 g ml−1; AF6710, 
R&D Systems), stained using a NorthernLights 557–conjugated 
secondary antibody (1:200; NL010, R&D Systems), and counter-
stained with 4′,6-diamidino-2-phenylindole (2 g ml−1; D1306, 
Thermo Fisher Scientific).
Laser Doppler perfusion imaging
Blood flow was measured on anesthetized animals 1, 7, 14, 21, 28, 
35, and 70 days after surgery using a PeriScan PIM 3 laser Doppler 
blood perfusion imager (Perimed, Stockholm, Sweden) (32). The 
hair covering the surgical site was removed the day before scanning, 
and the calvariae were cleaned using alcohol wipes immediately 
before data acquisition. Perfusion measurements were obtained 
from a circular region of interest superimposed over the defect.
Statistical analysis
Data are presented as means ± SD of n = 3 to 6 replicates from two 
to three biological donors unless otherwise stated. Statistical analyses 
between two groups were performed with Student’s unpaired t tests 
and between three or more groups with one-way analysis of variance 
(ANOVA), followed by Tukey’s multiple comparison post hoc test 
(GraphPad Prism 8.0, San Diego, CA) to determine significance 
(P < 0.05). Significance between groups is denoted with asterisks. A 
lack of significance between groups is indicated with “ns” and a line 
bridging nonsignificant groups. Correlations between bivariate 
parameters were modeled using simple linear least-squares regression 
analysis, and statistical analysis was performed using JMP software 
(SAS, Cary, NC).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/7/eaay2387/DC1
Fig. S1. Genes associated with immune system development are down-regulated with 
increasing time in culture.
Fig. S2. HA is degraded and removed from composite scaffolds during preconditioning in the 
bioreactor.
Fig. S3. Preconditioned scaffolds exhibit improved integration with host bone.
Table S1. Genes associated with immune system development down-regulated in 
preconditioned compared to naïve constructs.
Table S2. Genes associated with osteoblast differentiation and bone development 
up-regulated in preconditioned compared to naïve constructs.
Table S3. Genes associated with vasculature development up-regulated in preconditioned 
compared to naïve constructs.
View/request a protocol for this paper from Bio-protocol.
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